End Term Review of Kenya National Strategic Plan for Tuberculosis Leprosy and Lung Disease, 2019-2023
Kenya through the Division of the National Tuberculosis, Leprosy and Lung Disease Program (DNTLD-P) in collaboration with its stakeholders is conducting an End Term Review (ETR) of the National Strategic Plan for TB, Leprosy and Lung Disease, 2019-2023.
The review is aimed to take stock of the milestones achieved so far and offer opportunities to improve strategies and approaches in the programmatic management of the diseases in the country.
The need for the review has been informed by the fact that the current strategic plan runs between 2019 – 2023. Consequently, lessons learnt during the implementation period will inform the development of the 2024-2027 National Strategic Plan (NSP). In addition, it is paramount to note that the COVID-19 pandemic has threatened to reverse the gains made in the war against TB in Kenya. The findings of the review will further propose mitigation and acceleration of strategies that will ensure that the national and global set targets are achieved within the intended time.
The global community has also developed The End TB Strategy, Sustainable Development Goals (SDGs), and innovations during the implementation of the current NSP and thus the need to align Kenya’s strategies in line with the global guidance as a national obligation and to control these diseases.
The ETR which starts today will cover Nairobi, Kiambu, Machakos, Kajiado, Taita Taveta ‘ Samburu, Turkana, Kericho, Siaya, Busia, Kirinyaga and Meru.
Key areas of focus will include; Governance and political commitment, Programmatic management and coordination at the national and county level, Health financing and Universal Health Coverage, Multi-sectoral engagement, Case finding strategies, Laboratory services and surveillance, Pharmacovigilance, commodities, and supply chain management as well as Community health interventions and health promotion.
Partners supporting the review include County Governments, WHO, The Global Fund, USAID, CDC, TB ARC II, KCCB, Stop TB Partnership Kenya, ReSoK, EGPAF and Amref Health Africa in Kenya.